2月24日丨恒瑞医药(600276.SH) 公告称,公司子公司北京盛迪医药有限公司收到国家药监局下发的《受理通知书》,公司1类创新药SHR-1918注射液的药品上市许可申请获受理,且已被纳入优先审评程序。该药品用于治疗成人和12岁及以上的未成年人纯合子家族性高胆固醇血症(HoFH)患者。SHR-1918注射液是公司自主研发的血管生成素样蛋白3(ANGPTL3)单克隆抗体,通过抑制ANGPTL3的...
Source Link2月24日丨恒瑞医药(600276.SH) 公告称,公司子公司北京盛迪医药有限公司收到国家药监局下发的《受理通知书》,公司1类创新药SHR-1918注射液的药品上市许可申请获受理,且已被纳入优先审评程序。该药品用于治疗成人和12岁及以上的未成年人纯合子家族性高胆固醇血症(HoFH)患者。SHR-1918注射液是公司自主研发的血管生成素样蛋白3(ANGPTL3)单克隆抗体,通过抑制ANGPTL3的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.